Vor Bio amends agreement with RemeGen to add RC298 to exclusive license outside Greater China
VOR•VOR•VOR•VOR•Vor Bio will pay RemeGen $56 million upfront, including $10 million in cash and warrants for 2.3 million shares, to add RC298 to its exclusive license outside Greater China. RemeGen is eligible for up to $300 million in development milestones, and Vor Bio reaffirmed its cash runway into early 2029.
Vor Bio amended its agreement with RemeGen to add RC298 to the exclusive license outside Greater China. The company said an initial regulatory filing for RC298 in China is anticipated in the first half of 2027.
Vor Bio will provide RemeGen $56 million upfront, including $10 million in cash and warrants for 2.3 million shares. RemeGen is eligible for up to $300 million in development milestone payments, including $20 million for initial milestones. Vor Bio reaffirmed its cash runway into early 2029.
